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In a large consanguineous family of Turkish origin, genome-wide homozygosity mapping revealed a locus for recessive nonsyndromic
hearing impairment on chromosome 14q24.3–q34.12. Fine mapping with microsatellite markers deﬁned the critical linkage interval to
a 18.7 cM region ﬂanked by markers D14S53 and D14S1015. This region partially overlapped with the DFNB35 locus. Mutation analysis
of ESRRB, a candidate gene in the overlapping region, revealed a homozygous 7 bp duplication in exon 8 in all affected individuals. This
duplication results in a frame shift and premature stop codon. Sequence analysis of the ESRRB gene in the affected individuals of the
original DFNB35 family and in three other DFNB35-linked consanguineous families from Pakistan revealed four missense mutations.
ESRRB encodes the estrogen-related receptor beta protein, and one of the substitutions (p.A110V) is located in the DNA-binding domain
of ESRRB, whereas the other three are substitutions (p.L320P, p.V342L, and p.L347P) located within the ligand-binding domain. Molec-
ular modeling of this nuclear receptor showed that the missense mutations are likely to affect the structure and stability of these do-
mains. RNA in situ hybridization in mice revealed that Esrrb is expressed during inner-ear development, whereas immunohistochemical
analysis showed that ESRRB is present postnatally in the cochlea. Our data indicate that ESRRB is essential for inner-ear development and
function. To our knowledge, this is the ﬁrst report of pathogenic mutations of an estrogen-related receptor gene.Introduction
Autosomal-recessive nonsyndromic hearing impairment
(ARNSHI) is a genetically heterogeneous disorder. To
date, 67 loci for ARNSHI, referred to as DFNB loci, have
been mapped, and 24 of the causative genes have been
identiﬁed.1 The proteins encoded by DFNB genes vary
greatly with respect to their functions and their temporal
and spatial patterns of expression in the inner ear.
The majority of DFNB loci have been identiﬁed in fami-
lies with consanguineous marriages, and some of these
DFNB loci span large genomic regions containing many
genes. Linkage analysis in additional families segregating
hearing loss might result in the identiﬁcation of linkage
intervals that overlap known DFNB loci, thereby reﬁning
the critical regions and reducing the number of candidate
genes that would need to be screened for mutations. Ex-The Ampression proﬁling of genes preferentially or predominantly
expressed in the inner ear2–5 has also helped to prioritize
candidate genes for mutation screening. In addition,
large-scale microarray analysis of regenerating inner hair
cells from several avian species has recently revealed indi-
cations of a number of distinct pathways being important
for inner-ear development.6 Among these were known
pathways such as those involving NOTCH, TGFb, and
WNT, of which the latter is essential for planar cell polarity
and thus for stereocilia formation in inner-ear hair cells.7
Furthermore, components of other pathways, for instance
estrogen-receptor signaling, were found to be involved in
hair cell regeneration.6
In the present study, we describe the mapping of
ARNSHI segregating in a large consanguineous family
(TR-21) of Turkish origin to chromosome 14q24.3–
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DFNB35 (MIM %608565).8 One of the genes in this over-
lapping region was the estrogen-related receptor beta
gene ESRRB (MIM #602167) that is a member of the estro-
gen-receptor family. Sequence analysis of this gene in the
affected individuals of family TR-21, in the original
DFNB35 family, and in three additional DFNB35-linked
families from Pakistan indicate that mutations of ESRRB
are causative for early-onset hearing impairment.
Material and Methods
Subjects and Clinical Evaluations
Consanguineous family TR-21 of Turkish origin has eight affected
individuals (Figure 1). Other than hearing loss, general examina-
tions did not reveal any abnormalities in the participating indi-
viduals of family TR-21. Several participating family members un-
derwent otoscopic examination and pure-tone audiometry. Both
air conduction (frequencies 250–8000 Hz) and bone conduction
(500–4000 Hz) were evaluated in a sound-treated roomwith an In-
teracoustics AC5 audiometer (Interacoustics). In addition, we fur-
ther characterized thehearing loss in twoof the affected individuals
of this family (IV:5 and V:2, Figure 1C) by recording the auditory
Figure 1. Clinical Characterization and
Linkage Analysis of Family TR-21
(A) Binaural mean hearing-level thresholds
of affected individual V:2 (TR-21) in deci-
bels (dB) for each frequency in kilohertz
(kHz).
(B) Representative examples of transiently
evoked OAE recordings for individual V:2
(TR-21, left panel) and one control individ-
ual (right panel). The x axis shows the fre-
quencies at which OAE responses were
measured, and the y axis shows the emis-
sions in dB. Noise floor levels are shown
in black, and the responses to the stimuli
are shown in gray.
(C) Pedigree and haplotypes of family
TR-21 for STR markers within the linkage
interval. Flanking markers D14S53 and
D14S1015 are indicated in bold and italic.
The disease haplotype is indicated in black.
brainstem response (ABR) and otoacoustic
emission (OAE) spectra. Click-evoked
ABRs were measured with the ICS Chartr
MCU-90 system (GN Otometrics). Tran-
siently evoked OAE spectra were recorded
with aMadsenCapella Cochlear Emissions
Analyzer (GN Otometrics). Emissions of 6
dB or greater for at least three frequency
bands were accepted as a positive result in-
dicating functionally intact outerhair cells.
We addressed vestibular function and
vision by performing Romberg tests and
questionnaires including questions on
childhood motor development, insecure
feelings during walking in darkness or on an uneven surface, sport
activities,motion sickness, readingduringwalkingandvisual prob-
lems, and night blindness. For individuals IV:5 and V:2, computer-
ized tomography of the temporal bone, caloric testing, and fundu-
scopy were performed. In addition, complete urinalysis, urine-
concentration and -acidiﬁcation tests, tubular reabsorption of
phosphate, and measurements of plasma urea, creatinine levels,
andblood gaseswere carried out so that renal functions could be as-
sessed. Furthermore, 131 index patients from Turkish families that
have prelingual sensorineural hearing loss with indications of a re-
cessive mode of inheritance participated in this study. For all af-
fected individuals in this study, we excluded the GJB2 gene as the
causative gene by sequencing both exons and intron-exon bound-
aries. In addition, for all Turkishpatients fromconsanguineouspar-
ents, the known ARNSHI genes were excluded by homozygosity
mapping with ﬂanking microsatellite markers. Control DNAs
were used from 120 unrelated Turkish individuals. The clinical
features of affected subjects in the original DFNB35 family have
been described previously.8
Families PKDF191, PKDF159, and PKDF327 were ascertained
from the Punjab in Pakistan. All participating members of these
families were evaluated by a physician so that obvious extra-audi-
tory phenotypes associated with common syndromic forms of
deafness were ruled out. Air-conduction pure-tone audiometry126 The American Journal of Human Genetics 82, 125–138, January 2008
tests were performed on selected individuals under quiet ambient
conditions at octave frequencies ranging from 250 to 8000 Hz.
Vestibular function was evaluated by tandem gait and Romberg
testing. This study was approved by human-subject ethics com-
mittees in Pakistan, United States, Turkey, and the Netherlands.
All participating subjects were ascertained after obtaining written
informed consent.
Genetic-Linkage Studies
Genomic DNA was extracted from peripheral blood lymphocytes
with either salting out or nonorganic procedures.9,10 Genomic
DNA of ﬁve affected members of family TR-21 (V:2, V:3, V:7, V:8,
and V:9) was subjected to a genome-wide scan with a total of 382
short tandem repeat (STR) polymorphicmarkers (ABI Prism linkage
mapping set MD10.A) located on the 22 autosomal chromosomes.
The average distance and heterozygosity of the genotypedmarkers
were 10 cM and 0.76, respectively. The STRmarkers were ampliﬁed
bypolymerase chain reaction (PCR)with a RoboAmp4,200 (Isogen
Life Science) and were analyzed on an ABI prism 3700 genetic ana-
lyzer. The alleles were assignedwith theGeneMapper software (Ap-
plied Biosystems) and linkage designer software (Microsoft EXCEL
macro byGuy vanCamp,University of Antwerpen). In three Pakis-
tani families, STR polymorphicmarkers were typed for all of the re-
ported DFNB loci including DFNB35.8 Markers were ampliﬁed by
the polymerase chain reaction (PCR) on a Gene Amp PCR system
9700 (Applied Biosystems) and were analyzed on an ABI Prism
3100 Genetic Analyzer. For reﬁning the DFNB35 locus in the origi-
nal family, individuals were genotyped at the Center for Inherited
Disease Research (CIDR) with the Illumina ﬁne-mapping panel.
The calculation of the two-point log of odds (LOD) scores was
carried out with the easyLINKAGE program, version 3.03.11 An au-
tosomal-recessive mode of inheritance with complete penetrance
was assumed, and the disease allele frequency was set at 0.01.
For ﬁne mapping, all TR-21 family members were genotyped for
the following STR markers: D14S76, D14S61, D14S53, D14S42,
D14S983, D14S1035, D14S48, D14S1066, D14S280, D14S1015,
D14S977, and D14S81. The genomic localization of the markers
was derived from the Marshﬁeld map and the UCSC human ge-
nome database (build hg18, March 2006). For Pakistani families,
LOD scores were calculated with LINKMAP as described previ-
ously.12
Mutation Analysis
All exons and intron-exon boundaries of ESRRBwere ampliﬁed un-
der standard PCR conditions. Primer sequences are presented in
Table 1. Sequence analysis was performed with the ABI PRISM
Big Dye Terminator Cycle Sequencing V2.0 Ready Reaction kit
and the ABI PRISM 3730 DNA analyzer (Applied Biosystems). To
determine the presence of the p.Val342GlyfsX44 mutation in
healthy control individuals, we performed an ampliﬁcation refrac-
tory mutation system (ARMS)-like approach by using forward
primer 50-TTACGCTACACAGGGAAAGC-30, wild-type reverse primer 50-CTT
GAGCGTCACAAACTCCTCC-30, and mutant reverse primer 50-CCTT
GAGCGTCACAAACTCCAAAC-30. To determine the presence of the various
missense mutations in Pakistani control individuals, we ampliﬁed
the corresponding exons under standard PCR conditions and
sequenced them as described above.
Molecular Modeling
The structure of the DNA-binding domain of the estrogen receptor
beta ERB (PDBid ¼ 11o1) has been solved experimentally13 and isThe A99% identical to that of the ESRRB protein. The ligand-binding do-
main shows high sequence similarity with the corresponding do-
main of ESRRG (PDBid ¼ 1kv6).14 The crystal structure of ESRRG
was used as a template for building a model of the ligand-binding
domain of the human ESRRB protein. Modeling was performed
with the WHAT IF software15 with standard parameter settings
and protocols as described previously.16,17 This modeling is
straightforward because the percentage sequence identity is high
(79%) and all key residues are conserved between the template
and the model. The effects of the four missense mutations were
analyzed with the WHAT IF/YASARA TwinSet.18
Tissue Distribution of ESRRB Isoforms
Total RNA from human placenta, adult brain, testis, kidney, and
retina and from fetal heart, skeletal muscle, liver, and lung was
obtained from Clontech Laboratories. Total RNA from cochlea of
16- to 22-week-old human fetuses was isolated with RNAzol B
(Campro Scientiﬁc) as described previously.3 For cDNA synthesis,
2 mg of total RNAwas incubated with 5 ng/ml of random hexamers
[pd(N)6; Pharmacia] and 0.3 mM dNTPs (Invitrogen Life Sciences).
Subsequently, cDNA was synthesized with the M-MLV Reverse
Transcriptase kit (Invitrogen Life Sciences) with a ﬁnal concentra-
tion of 10 mM DTT, 11 U Reverse Transcriptase, and 0.33 U RNA-
guard (American Biosciences) per reaction.
For detection of the distribution patterns of the ESRRBlong,
ESRRB-D10, and ESRRBshort isoforms19 in various human tissues,
RT-PCR was carried out with the GC-rich PCR system (Roche) with
forward primer 50-CTATAGCGTCAAACTGCAGGGCAAAGTG-30 and reverse
primer 50-CTGCTCTTGGCCAACCTGCCCTCT-30 for the ESRRBlong isoform,
forward primer 50-TGACGACAAGCTGGTGTACG-30 and reverse primer 50-
ATCCCTGCTTGTGAAGGCAG-30 for the ERRSB-D10 isoform, and forward
primer 50-TGACGACAAGCTGGTGTACG-30 and reverse primer 50-TCTGTAGG
TGGGCATTGGTC-30 for the ESRRBshort isoform. As a control, glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) was ampliﬁed with
forward primer 50-ACCACAGTCCATGCCATCAC-30 and reverse primer 50-
TCCACCACCCTGTTGCTGTA-30. PCR products were analyzed via agarose
gel electrophoresis and sequenced as described above.
Digoxigenin Labeling of cRNA In Situ
Hybridization Probes
To obtain probes for RNA in situ hybridization, we generated PCR
products that correspond to the 30 end of murine Esrrb (GenBank
ID AK052256). PCR reactions were carried out with forward primer
50-CATCGTGTACCGCTCGCTC-30 and reverse primer 50-CAGGAGCATCCACTG
AGAAC-30. Amplimers were cloned in the pCR4-TOPO vector with
Table 1. Primer Sequences Used to Amplify ESRRB
Exon Forward Primer Reverse Primer
1 50-atgtttccgcagcatttatc-30 50-gccacatgctctctaaatcc-30
2 50-agcaaccagtactcaccagg-30 50-ggagaaaaggaggcagaaac-30
3 50-atgcaatgtgaccctagagc-30 50-aagacagcatggtctgcatc-30
4 50-taatgccagaaacttgctcc-30 50-cacagaagtaccgctccaac-30
5 50-tgctttgagaacactagggg-30 50-aagaaattccaattcccacc-30
6 50-ggatgcgccattactgttag-30 50-cccaagatccacattgtctc-30
7 50-ggagctcttaggaacccaac-30 50-tcctctccaatgctacaagg-30
8 50-ttacgctacacagggaaagc-30 50-cttaggaaatgctcagccag-30
9 50-acctcttgagaaatgtcccc-30 50-catgatacaggggttgaagg-30
10 50-atgcccacctacagacagac-30 50-aagctgagtggaaactgtgg-30
11 50-tcccaggaaactcctctacc-30 50-agctgctctgcagtttgtg-30
12 50-ctcactgtgctgtgtccttg-30 50-atggaccccttcagtaccag-30merican Journal of Human Genetics 82, 125–138, January 2008 127
the TOPO TA cloning kit (Invitrogen) and sequenced with T7 and
T3 sequencing primers. Subsequently, PCR reactions were per-
formed with T7 and T3 polymerase-speciﬁc primers with the
pCR4-TOPO construct as a template. We generated digoxigenin
(DIG)-cRNA probes by incubating 400 ng of these PCR products
with 2 ml 103 DIG RNA labeling mix (Roche), 2 ml T3 (sense) or
T7 (antisense)-dependent RNA polymerase (Roche), 2 ml 103 Tran-
scription buffer (Roche), and RNase-free H2O added to a ﬁnal vol-
ume of 20 ml, at 37C for 2 hr. To terminate the reaction, we added
2 ml of 0.2 M EDTA (pH 8.0). The cRNA probe was ethanol precip-
itated and dissolved in RNase-free H2O. DIG concentrations were
determined by dot-blot analysis on HybondNþ nylonmembranes
(Amersham Biosciences), compared with a control DIG-cRNA
probe (Roche), and stored at 80C.
RNA In Situ Hybridization
Mouse embryos collected at various embryonic stages (E12.5–
E18.5) as well as eyes of adult mice (P90) were frozen on crushed
dry ice and stored at 80C. The tissues were embedded in Tissue-
Tek O.C.T. compound (Sakura Finetek) and sagitally cut into 16
mm sections at temperatures of 16C to 20C. Serial sections
were collected on SuperFrost Plus microscope slides (Menzel-
Gla¨ser). After quick drying, these sections were stored at 80C.
The DIG-labeled cRNA probes were hybridized to the mouse-tissue
sections as follows: Samples were rapidly defrosted and ﬁxed in 4%
paraformaldehyde in PBS (pH 7.4) for 10 min. Slides were washed
three times in PBS (pH 7.4) and acetylated for 10 min in a solution
containing 3.3 ml triethanolamine, 0.438 ml 37% HCl, and 0.625
ml acetic anhydride in a ﬁnal volume of 250 ml H2O. Slides were
washed three times for 5 min in PBS and prehybridized for 2 hr at
room temperature (RT) with hybridization mix [50% deionized
formamide, 53 SSC, 53 Denhardt’s solution, 250 mg/ml brewer’s
yeast tRNA (Roche), and 500 mg/ml sonicated salmon sperm DNA
(Sigma)]. Subsequently, hybridization was performed overnight at
72Cwith 150 ml hybridizationmix containing 400 ng/ml DIG-la-
beled probe, washed brieﬂy at 72C in 23 SSC, and subsequently
washed for 2 hr at 72C in 0.23 SSC. Slides were allowed to cool,
transferred to 0.23 SSC at RT for 5 min, and subsequently trans-
ferred to buffer 1 (100 mM Tris-HCl [pH 7.4], and 150 mM NaCl).
Slides were incubated for 1 hr at RT with 10% heat inactivated fe-
tal-calf serum (FCS) in buffer 1 and then incubated overnight at
4Cwith 0.7ml 1%heat inactivated FCS in buffer 1with 1:5000 di-
luted anti-DIG-AP, fab fragment fromsheep (Roche)per slide. Slides
were washed three times in buffer 1 and once in buffer 2 (100 mM
Tris-HCl [pH9.5], 100mMNaCl, and50mMMgCl2) atRT.A total of
1mlof staining solution [200ml ofNBT-BCIP stock solution (Roche),
1 ml Levamisole (Sigma, 2.4 mg/ml), and 8.8 ml buffer 2 per 10 ml]
was applied to the slides, and staining was allowed to take place
overnight in a dark environment. Subsequently, the slides were
washed once in T10E5 (10 mM Tris [pH 8.0] and 5 mM EDTA) for
the reaction termination. To increase structural detail, we incu-
bated some slides in Nuclear Fast Red (Sigma) for 10 s. Slides were
dehydrated and sealed with Entellan rapid mounting media
(ProSciTech). Images were recorded on a Zeiss Axioskop2 plus
microscope with a Sony power HAD DXC-950P 3CCD color video
camera.
Antibodies
A primary polyclonal antibody directed against mouse Esrrb
(Ab19331: aa 376–388, peptide DYELSQRHEEPRR) was purchased
from Abcam. Speciﬁcity of the ESRRB antiserum was conﬁrmed128 The American Journal of Human Genetics 82, 125–138, Januarby preincubation of the antiserum with 10 mg of the peptide
(Princeton BioMolecules) used as antigen prior to immunohisto-
chemistry (data not shown). Mouse monoclonal antibody M3F7
(DSHB) directed against collagen type IV and mouse monoclonal
antibody RNF402 (Abcam) directed against the 200 kDa neuroﬁla-
mentheavy chainwere used asmarkers. Secondary antibodieswere
acquired fromMolecular Probes (Invitrogen).
Immunohistochemistry
Cochleae from P4 rats were isolated and ﬁxed as described be-
fore.20 After ﬁxation, cryosections were made at a thickness of
10 mm and treated with 0.01% Tween-20 in PBS; this was followed
by a blocking step with blocking solution (0.1% ovalbumin and
0.5% ﬁsh gelatin in PBS). Antibodies diluted in blocking solution
were incubated overnight at 4C. Secondary antibodies were also
diluted in blocking solution and incubated for 1 hr at room tem-
perature. Sections were embedded with Prolong Gold Antifade
(Molecular Probes). Pictures were made with an Axioskop2 Mot
plus ﬂuorescence microscope (Zeiss) equipped with an AxioCam
MRC5 camera (Zeiss). Images were processed with Axiovision 4.3
(Zeiss).
Results
Clinical Characterization
Affected individuals of family TR-21 have bilateral, severe-
to-profound sensorineural hearing loss (Figure 1A), and
acoustic brainstem responses were absent in affected indi-
viduals (data not shown). Transient otoacoustic emission
spectra (TEOAEs) were absent in two individuals (IV:5 and
V:2, measured at the age of 48 and 23 years, respectively)
that were tested (Figure 1B), indicating a deﬁciency of outer
hair cell function in these patients. For these two individ-
uals, computerized tomography of the temporal bone and
caloric testing for evaluation of the vestibular function
were performed, and no abnormalities were found. In the
affected family members, there were no indications of a
visual problem, kidney failure, or morphological features
that suggested a syndromic form of hearing loss.
Linkage and Mutation Analyses
Genome-wide homozygosity mapping revealed only one
interval located on chromosome 14q24–31. Fine mapping
with microsatellite markers in the complete family reﬁned
the linkage interval to 18.7 cM between markers D14S53
and D14S1015 (Figure 1C) with a maximum two-point
LOD score of 5.45 for marker D14S48. The linkage interval
partially overlapped with the DFNB35 locus for which the
causative gene had not yet been identiﬁed.8 Within the
original DFNB35 family, the linkage interval was reduced,
and rs1035159 was determined to be the distal ﬂanking
marker (Figure 2A). Therefore, only a 1.1 cM-region,
ﬂanked by markers D14S53 and rs1035159, is shared be-
tween theDFNB35 locus and the linkage interval described
here (Figure 2B). This shared interval contains seven
RefSeq genes and includes only exons 5–12 of the estro-
gen-related receptor beta gene ESRRB. This gene wasy 2008
represented in a cochlear cDNA library that was generated
via a suppression subtractive hybridization technique.3
Sequence analysis of ESRRB in an affected individual
of family TR-21 revealed a 7 bp duplication in exon 8
(c.1018_1024 dupGAGTTTG; Figure 2C), and such a dupli-
cation is predicted to change the reading frame and cause
premature termination of the protein (p.V342GfsX44).
Subsequently, mutation analysis was performed in the
original DFNB35 family8 as well as in three other families
of Pakistani origin (PKDF159, PKDF191, and PKDF327) seg-
regating severe-to-profound hearing loss linked to the
DFNB35 interval. In the affected individuals of the origi-
nal DFNB35 family, a homozygous missense mutation
(c.1024G/T; Figure 2D) was identiﬁed that is predicted to
substitute a leucine residue for a valine residue (p.V342L).
Also in the other DFNB35-linked families, missense muta-
tions were identiﬁed. In family PKDF191, affected individ-
ualswerehomozygous for an alanine-to-valine substitution
(c.329C/T; p.A110V), whereas in family PKDF159, a leu-
cine-to-proline change (c.959T/C; p.L320P) was detected
(Figure 3). Similarly, in family PKDF327, a leucine-to-pro-
line change (c.1040C/T; p.L347P) (Figure 3) was segregat-
ing and homozygous in the affected individuals. In all ﬁve
families, the homozygous mutations cosegregated with
hearing impairment and were not present in at least 120
ethnically matched normal-hearing individuals. In addi-
tion to the mutations described above, one other variant
(c.1156C/T; p. P386S) was present homozygously in
Figure 2. Linkage Interval and Muta-
tion Analysis of ESRRB in Family TR-21
and the Original DFNB35 Family
(A) Haplotype analysis for part of the orig-
inal DFNB35 family reduced the DFNB35
locus. The recombination event in V:1
was determined to have occurred between
rs8020517 and rs1035159.
(B) Schematic representation of the re-
duced DFNB35 locus and the critical region
identified in family TR-21. Genetic posi-
tions of the markers, according to the
Marshfield map, are shown in centimorgan
(cM). The intervals share a 1.1 cM (0.7 Mb)
region flanked by markers D14S53 and
rs1035159, encompassing part of ESRRB.
(C) Partial sequence of ESRRB from an af-
fected individual of family TR-21 homozy-
gous for the 7 bp duplication (c.1018_
1024 dupGAGTTTG; depicted in red), a
family member with two wild-type alleles
and a heterozygous carrier. The effect of
the mutation at the amino acid level is in-
dicated above the sequence.
(D) Partial sequence of ESRRB from an affected member of the original DFNB35 family, carrying the nucleotide substitution c.1024G/T
homozygously, from a family member with two wild-type alleles and from a heterozygous carrier. The predicted amino acid substitution
(p.V342L) and the surrounding amino acids are indicated above the sequence.Figure 3. Mutation Analysis of ESRRB
in Additional DFNB35 Families
Pedigrees of families PKDF191, PKDF159,
and PKDF327 in which linkage to the
DFNB35 locus was suggested. Sequence
traces of ESRRB carrying the respective
nucleotide substitutions c.329C/T,
c.959T/C, and c.1040C/T from an af-
fected and normal-hearing individual of
these families are shown below the pedi-
grees. The predicted amino acid substitu-
tions are p.A110V, p.L320P, and p.L347P,
respectively.The American Journal of Human Genetics 82, 125–138, January 2008 129
Table 2. Mutations in ESRRB that Cause Recessive Hearing Loss
Family Max. Two-Point LOD Score Mutationa Amino Acid Change Predicted Effect on ESRRB
TR21 5.45 c.1018_1024 dupGAGTTTG p.V342GfsX44 Frame-shift; premature truncation
Pedigree 2 (DFNB35) 5.53 c.1024G/T p.V342L Structural defect; ligand-binding domain
PKDF159 2.06 c.959T/C p.L320P Structural defect; ligand-binding domain
PKDF191 2.75 c.329C/T p.A110V Structure or function; DNA-binding domain
PKDF327 5.10 c.1040C/T p.L347P Structural defect; ligand-binding domain
Overview of the families presented in this study with mutations in ESRRB. Shown are the family name, maximum two-point LOD scores calculated for markers
within the DFNB35 locus, the nucleotide change, and the predicted effect of the mutation at the amino acid level and on the ESRRB protein.
a Nucleotide positions are numbered relative to the first nucleotide of the translation open reading frame found in RefSeq NM_004452.both the original DFNB35 family and family PKDF191. This
variant, however, was also present in 9 out of 100 Pakistani
control individuals, homozygously in two persons, and
was, therefore, considered to be a polymorphism. All dis-
ease-causing variants detected in the various families and
the maximum LOD scores indicating linkage to DFNB35
are presented in Table 2.
For determination of the possible involvement of ESRRB
mutations in the Turkish hearing-impaired population, 83
index patients from consanguineous families were geno-
typed for markers ﬂanking the DFNB35 locus. Seven of
these patients were found to be homozygous for these
markers. The ESRRB gene was sequenced in these seven pa-
tients, as well as in 48 index patients from nonconsangui-
neous families. In one patient, a nonsynonymous change
p.T389M (c.1166C/T) was identiﬁed in the heterozygous
state and was not present in 120 ethnically matched con-
trol individuals. However, in this patient a second mutant
allele of ESRRB was not found, and therefore, the disease-
causing nature of this missense variant is uncertain.
Structural Analysis of the ESRRB Mutants
ESRRB encodes the estrogen-related receptor protein beta
that is a member of the nuclear hormone receptor (NHR)
family. One of the NHR subfamilies is composed of the
estrogen receptors (ERs), the estrogen-related receptors
(ESRRs), and the steroid receptors (SRs).21 In general, these
proteins share a zinc ﬁnger C4 DNA-binding domain at
their N terminus and a ligand-binding domain that is
locatedmore C terminally (Figure 4A). Themain difference
between these three groups is that the ESRRs are consid-
ered to be orphan receptors, whereas the ERs and SRs are
regulated by molecules such as estrogens and glucocorti-
coids.22,23 Although no endogenous ligand has yet been
identiﬁed for the ESRR proteins, the sequence of their
ligand-binding domains are well conserved (Figure 4B).
The ligand-binding domain of nuclear hormone receptors
is a highly organized structure containing 12 a helices
(Figures 4B and 4C).
The p.A110V change found in family PKDF191 is located
in the DNA-binding domain of the ESRRB protein and is
likely to disturb the structure of this domain (data not
shown). The three other missense mutations identiﬁed in
the Pakistani families substitute amino acids that are
located in the ligand-binding domain of ESRRB. Leucine130 The American Journal of Human Genetics 82, 125–138, January320, replaced by a proline in family PKDF159 (p.L320P), is
located in helix seven of this domain and conserved in ver-
tebrate ESRRB proteins as well as in ESRRA and ESRRG
(Figure 4B). In general, the introduction of proline residues
within ahelices reduces the stability of the helix, and there-
fore, thismutationwill probably disrupt the structure of he-
lix seven and the complete ligand-binding domain. In addi-
tion, the loss of the leucine side chain abrogates anumberof
hydrophobic interactions (Figure 4D). The valine residue
that is replaced by a leucine in the original DFNB35 family
(p.V342L) is less conserved. In the mouse ESRRB sequence,
amethionine residue is present at this position, although in
chicken and zebraﬁsh ESRRB, the valine is conserved. In the
other ESRRproteins and inERA, the valine residue that is lo-
cated within helix eight (Figure 4B) is also conserved. How-
ever, in ERB there is a leucine present in that position. The
substitution of a leucine for this valine residue results in
the occurrence of a somewhat larger side chain that bumps
into themolecular surface of helix one (Figure 4E), and this
substitution is predicted to reduce the strength of the inter-
action between helix one and eight. Finally, the leucine-
to-proline change (p.L347P) in family PKDF327 again sub-
stitutes a proline for a leucine that is conserved in all ESRRB
proteins and in human ESRRA and that is located in helix
eight (Figure 4B). As mentioned for the p.L220P mutation,
this leucine-to-proline change will reduce the stability of
the a helix and disrupt the conformation of the ligand-
binding domain. In addition, and as shown in Figure 4F,
the leucine side chain is facing a number of other leucine
residues that together form a tightly packed hydrophobic
cluster. The presence of a proline residue at that position
would also result in the loss of this cluster of hydrophobic
interactions (Figure 4F). In summary, the molecular model-
ing data predict that mutations of ESRRBwill result in con-
formational changes near the substituted amino acids or
decreased helix stability and are therefore likely to affect
the stability and function of the complete ligand-binding
domain. A detailed overview of the molecular modeling is
available (see Web Resources).
Cochlear Expression of the Different ESRRB Isoforms
Alternative splicing of the ESRRB gene gives rise to three
major isoforms (Figure 5A) of which the distribution in var-
ious tissues has previously been studied.19 To determine
the presence of these three isoforms in cochlear tissue,2008
we performed RT-PCR analysis by using primers that
speciﬁcally amplify the transcripts encoding the various
isoforms. The transcript for the small isoform of ESRRB
(ESRRBshort) was detected in all tissues examined. The
transcript that lacks exon 10 (encoding ESRRB-D10) was
mainly expressed in testis, kidney, cochlea, and retina, al-
though some weak expression was observed in the other
tissues examined. Interestingly, the transcript that con-
tains all exons and encodes the ESRRBlong isoform was
detected mainly in testis and cochlea, although a weak
band was also observed in retina (Figure 5B). These data
show that all isoforms are abundantly expressed in human
cochlear tissue and that the ESRRBlong isoform appears to
be preferentially expressed in cochlea and testis.
Expression of Esrrb during Inner-Ear Development
To characterize the expression of Esrrb during murine
embryogenesis, we hybridized Esrrb-speciﬁc sense and anti-
sense cRNA probes to sagitally cut embryo sections of vari-
ous developmental stages. Whereas no signal was detected
in any of the sections analyzed with the sense probe (data
not shown), a strong signal in the antisense probed sections
was visible in a restricted number of developing tissues. At
embryonic day 12.5 (E12.5), staining was observed in the
midbrain, the spinal cord, the metanephros, and the adre-
nal primordium (Figures 6A and6B). In addition, a very spe-
ciﬁc signalwaspresent in the regionof thedeveloping inner
ear, both at E12.5 (Figure 6C) andE14.5 (Figure 6D). The ob-
served staining in the midbrain and spinal cord remained
throughout embryonic development, although signal was
not detected in the developing kidney and adrenal gland
after E14.5 (data not shown). At E16.5, Esrrb expression is
present in the developing cochlea as well as the developing
vestibular system (Figures 6E–6H). In addition, stainingwas
observed in the vestibular ganglion (Figure 6H). Esrrb ex-
pression in the inner ear is even more prominent at E18.5
in the cochlear turns, the ampullae of the semicircular
canals, the utricle, and the vestibular ganglion (Figures 6I–
6L). To obtain more structural detail, a number of sections
of an E18.5 embryo were counterstained with Nuclear Fast
Red. Detailed images of the inner-ear region show speciﬁc
staining in the developing stria vascularis in the cochlea
(Figure 6M), a subset of nonsensory epithelial cells of the
utricle and the ampullae in the vestibulum (Figures 6N
and 6O), and part of the cells in the developing vestibular
ganglion (Figure 6P).
In the eyes of adult mice (P90), a clear and strong signal
was detected in the photoreceptor layer of the retina (data
not shown), although during development, no signal was
detected in the eye. This implies that the expression of
Esrrb within a tissue is different when comparing develop-
mental and adult stages. In summary, the in situ hybridiza-
tion data show that Esrrb is highly expressed during inner-
ear development in nonsensory epithelial cells of both the
cochlea and the vestibulum. In addition, the gene is ex-
pressed in the developing vestibular ganglion.The AmESRRB Expression in Inner Ear
For determination of the expression of Esrrb at the protein
level, inner-ear sections derived from rats sacriﬁced at post-
natal day four (P4) were incubated with antibodies directed
against ESRRB, together with a set of markers. In the co-
chlea, ESRRB was found to be expressed in cells of meso-
thelial origin in the spiral limbus and the supporting cells.
Moderate staining was also observed in Reissner’s mem-
brane, the stria vascularis, and the spiral ligament (Figures
7A and 7D). In addition, ESRRB was highly expressed in
the nerve ﬁbers and the spiral ganglion cells (Figure 7D).
With an antibody against collagen type IV as a basement
membrane marker24 (Figure 7B), it was shown that ESRRB
is expressed on the mesothelial side of the basilar mem-
brane (Figure 7C). Because ESRRB was found to be ex-
pressed in the nerve ﬁbers and the spiral ganglion cells,
an antibody directed against the heavy chain of neuroﬁla-
ments (NFH) was used to speciﬁcally stain these struc-
tures25 (Figure 7E). This showed partial colocalization of
NFHwith ESRRB (Figure 7F). A magniﬁed image of NFH ex-
pression in the organ of Corti shows that these nerve ﬁbers
protrude from the habenula perforata and contact the in-
ner and outer hair cells at their basolateral side (Figure 7H).
No ESRRB expression was detected in the sensory cells in
the organ of Corti, but only in the supporting cells (Figures
7G and 7I). The localization of ESRRB and NFH in the nerve
ﬁbers is depicted in more detail in Figures 7J–7L. ESRRB
and NFH also are found to colocalize in the spiral ganglion
neurons and ﬁbers (Figures 7M–7O), although their distri-
butions in these cells is not exactly the same (Figure 7O). In
the ganglion cells of the vestibulum, a similar pattern of
colocalization between ESRRB and NFH was observed
(data not shown).
Discussion
In this study, genome-wide homozygosity mapping re-
vealed a locus for nonsyndromic hearing impairment in
an 18.7 cM interval on chromosome 14q24.3–q34.12,
partly overlapping with the DFNB35 locus.8 One of the
genes in the overlapping region was ESRRB. Sequence anal-
ysis of this gene revealed a 7 bp duplication in the affected
members of family TR-21 (p.V342GfsX44), whereas four
missense mutations in ESRRB were identiﬁed in the origi-
nal DFNB35 family and three other families from Pakistan.
ESRRB is a member of the nuclear-hormone-receptor
family of transcription factors. All family members share
two functional domains, a DNA-binding domain and a
ligand-binding domain. The 7 bp duplication in ESRRB of
family TR-21 results in a frame shift and premature protein
termination. Because the mutation is not in the last exon
of the gene, the mRNAmolecule might be a target for non-
sense-mediated RNA decay.26 Alternatively, an aberrant
protein might be present in the cells that would lack an
intact ligand-binding domain and thus probably would
not function properly.Whereas the substitution of a valineerican Journal of Human Genetics 82, 125–138, January 2008 131
Figure 4. Molecular Modeling for ESRRB Missense Mutations
(A) Schematic representation of human ESRRB. The predicted zinc finger C4 DNA-binding domain (DBD) and the ligand-binding domain
(LBD) are depicted in red and blue, respectively.
(B) Sequence comparison of the ligand-binding domains of five vertebrate ESRRB proteins, the two other human ESRR proteins ESRRA and
ESRRG, and the human estrogen receptors ERA and ERB. Residues identical in all sequences are white on a black background, whereas
similar amino acids are black on a light-gray background. Residues that are present in at least five of the proteins are indicated in white
on a gray background. The missense mutations affecting amino acids in the ligand-binding domain are indicated by arrows. The positions
of the various a helices in the ligand-binding domain are marked above the sequence. Species abbreviations are as follows: Hs, Homo
sapiens; Mm, Mus musculus; Rn, Rattus norvegicus; Gg, Galus gallus; and Dr, Danio rerio. Accession numbers of the various human protein
sequences: Hs ESRRB, NP_004443, Mm ESRRB, NP036064; Rn ESRRB, AAR89824; Gg ESRRB: XP001235147; Dr ESRRB: XP00133980;
Hs ESRRA, AAH92470; Hs ESRRG, P62509; Hs ERA, AAI28575; and Hs ERB, NP_001035365.
(C) Molecular modeling of the ligand-binding domain of the human ESRRB protein. The structure was deduced from the known ESRRG
structure.14 The various helices are presented by cylinders. The three amino acids that are affected by the missense mutations, marked
by arrows in Figure 4B, are indicated in green.
(D) Graphic representation of the predicted effect of the p.L320P mutation. The leucine residue is depicted in green, whereas the side
chain of the proline residue is presented in red. The absence of the leucine side chain results in the loss of hydrophic interactions with
residues located in helix ten and eleven.
(E) Graphic representation of the predicted effect of the p.V342L mutation. The substitution of a leucine for a valine residue results in
a larger side chain (leucine side chain is depicted in red; original valine residue in green) that does not fit into the molecular surface
between helix eight and helix one, here presented as a grayish shade.132 The American Journal of Human Genetics 82, 125–138, January 2008
residue for a fully conserved alanine (p.A110V) affects the
DNA-binding domain of ESRRB, the other missense muta-
tions affect amino acids in the ligand-binding domain. The
p.A110V does not affect a residue directly involved in
DNA-contact, but it is likely to disrupt the 3D structure
of the DNA-binding domain. Missense mutations in this
domain of other nuclear hormone receptors are known
Figure 5. Tissue Distribution of ESRRB Isoforms
(A) Schematic overview of transcripts encoding the three ESRRB
isoforms (exons are numbered). The protein corresponding to the
long isoform is presented above the isoforms, showing that all iso-
forms contain both the DNA-binding domain (DBD) and the ligand-
binding domain (LBD). Arrows indicate the protein coding regions
in the three different transcripts. The gray part at the 30 end of the
ESRRBshort isoform represents an extension of exon 9 that was due
to an alternative splicing event. Relative positions of the primers
used for amplification of the various transcripts are indicated be-
low the transcripts. The asterisk indicates the relative position
of the epitope used for raising the antiserum for immunohisto-
chemical analysis (see Figure 7).
(B) Tissue distribution of transcripts encoding the three different
ESRRB isoforms. RT-PCR analysis was performed on total RNA from
the various tissues. The expression of GAPDH (lower panel) was
used as a control.The Ato cause speciﬁc phenotypes such as androgen insensitiv-
ity syndrome27 and maturity-onset diabetes.28
The ligand-binding domain of estrogen-receptor-family
members generally consists of twelve a helices, although
the second helix is absent in some family members includ-
ing ESRRB. The a helices fold together with a b sheet into
a three-layered helical sandwich. Activation of a receptor
depends on the binding of an agonist and one or more co-
factors. The ligand-binding pocket is formed by the b sheet
and helices three, ﬁve, six, and eleven. Upon ligand bind-
ing, helix twelve becomes repositioned into a groove be-
tweenhelix three andeleven, thereby forminganewgroove
for coactivator binding. In contrast, antagonist bindingpre-
vents helix twelve from relocating, after which corepressors
occupy the available space in the groove between helix
three and eleven and prevent activation of the receptor.29
Although the missense variants found in the ligand-bind-
ing domain do not affect the helices directly involved in li-
gand binding, the structural changes that occur near the
substituted amino acids probably inﬂuence the structure
or stability of the complete domain. In addition, leucine-
to-proline changes within an a helix are likely to disrupt
the helical conformation. The p.V342L substitution in he-
lix eight is predicted to disrupt the interaction between he-
lix eight andhelix one andmight impair the functionof the
ligand-binding domain. This is supported by other muta-
tions, either in helix eight of the estrogen receptor30 or
in helix one of the androgen receptor,31 that alter the bind-
ing afﬁnity of the ligand. In addition, hydrophobic interac-
tions between helix one and helix eight have been reported
to be required for maintenance of the conformation of
the receptor PPARg,32 and it is has been suggested that
these results can be extrapolated to other members of the
nuclear receptor family, including the estrogen-related
receptors.
Alternative splicing of ESRRB results in the occurrence of
three isoforms,19 two of which were found to be ubiqui-
tously expressed. Interestingly, the ESRRBlong isoform
had a narrow tissue distribution and was abundant in
cochlea and testis. These results are mainly in accordance
with the observed distribution described by Zhou and
others.19 Although themutations found in this study affect
all protein isoforms, it is tempting to speculate that the
defect in ESRRBlong underlies the nonsyndromic hearing
impairment. Because this isoform is also highly expressed
in testis, one might expect male individuals to have altered
testicular function. One affected male individual of family
TR-21 (IV:5), however, has reproduced, indicating that
affected males with DFNB35 can be fertile. On the other
hand, many other genes that cause nonsyndromic hearing
loss are abundantly expressed outside the cochlea, for in-
stance DFNB3133 and PCDH15.34 Therefore, a dysfunction(F) Graphic representation of the predicted effect of the p.L347P mutation. The leucine residue is depicted in green, whereas the side
chain of the proline residue is presented in red. The side chain of leucine 347 interacts with a number of other leucine residues (side
chains in gray) located in helix nine. These interactions are lost by substituting proline for leucine. Images as presented in (C)–(F)
were made with the YASARA program.18merican Journal of Human Genetics 82, 125–138, January 2008 133
Figure 6. RNA In Situ Hybridization for Esrrb on Mouse Sagittal Sections
(A–C) At embryonic day E12.5, images of the medial side of the head (A), the body (B), and the lateral side of the head (C) are presented.
Regions that show specific staining are indicated with arrowheads and are as follows: midbrain (1), mantle layer in the ventral side of the
spinal cord (2), metanephros (3), adrenal primordium (4), and developing inner ear (5).
(D) At E14.5, staining in the developing inner ear (6).
(E–H) Serial sections of embryo heads at E16.5 in (E) and (G) with the corresponding inner-ear region enlarged in (F) and (H), respec-
tively. Staining was observed in specific parts of the developing cochlea (7) and vestibulum (8) and the developing vestibular ganglion
(9).
(I–L) Serial sections of embryo heads at E18.5 in (I) and (K) with the indicated inner-ear region enlarged in (J) and (L), respectively.
Staining was present in the turns of the cochlea (7), in the ampulla (10) and the utricle (11) of the vestibulum, and in the vestibular
ganglion (9).
(M–P) Detailed images of the inner ear at E18.5, showing expression in (M) the developing stria vascularis in the cochlea, (N) a subset of
the nonsensory epithelial cells in the utricle, and (O) the nonsensory epithelium in the ampulla and in (P) cells of the vestibular ganglion.
Sections were counterstained with Nuclear Fast Red for an increase of structural detail. The following abbreviations are used: ec, endo-
lymphatic compartment; and se, sensory epithelia. In (A), the compass shows the orientation of the embryos in all panels; R, rostral;
V, ventral; C, caudal; and D, dorsal.of the other two ESRRB isoforms might contribute to the
phenotype.
During mouse embryogenesis, there is a very speciﬁc dis-
tribution pattern of Esrrb transcripts in the developing in-
ner ear. Previously, RNA in situ hybridizations in zebraﬁsh
have shown transcripts of the ESRRB ortholog to be present
in the diencephalon, the trigeminal ganglia, and in the
anterior and posterior ganglia of the lateral line, which is
structurally and functionally related to the mammalian in-
ner ear. No expression was observed in the vestibular organ
of the ﬁsh.35134 The American Journal of Human Genetics 82, 125–138, JanuaryWithin the developing inner ear of the mouse, we found
Esrrb expression in the nonsensory epithelia of the vestibu-
lum, the developing stria vascularis, and lateral wall of
the cochlea and in the vestibular ganglion. Very recently,
Chen and Nathans36 showed a similar distribution of
Esrrb postnatally, namely in the marginal cells of the stria
vascularis in the cochlea and in analogous structures in
the vestibular system, both by in situ hybridization and by
immunohistochemistry. Our immunohistochemical analy-
sis showed a broader expression of ESRRB within the early
postnatal cochlea. All of the various cochlear cells that2008
Figure 7. Immunohistochemical Analy-
sis of ESRRB Expression in Inner Ear of
P4 Rats
The relative position of the epitope used to
raise the antiserum is depicted in Figure 5A.
(A–C) Overview of the cochlea. ESRRB ex-
pression is mainly observed in mesothelial
cells of the spiral limbus (1) and the basilar
membrane (2) and in the supporting cells of
the organ of Corti (3). In addition, moder-
ate expressionwas observed in the stria vas-
cularis (sv), the spiral ligament (sl), and
some cells of mesothelial origin in Reiss-
ner’s membrane (rm). Collagen type IV
staining shows the cochlear basement
membranes; a merged picture shows that
ESRRB is expressed on the mesothelial side
of the basement membrane. The following
abbreviations are used: sm, scala media;
spv, spiral vessel; and hp, habenula per-
forata.
(D–F) Overview of the cochlea including the
organ of Corti, nerve fibers, and the spiral
ganglion. In addition to the expression de-
scribed in (A), ESRRB is abundantly present
in the nerve fibers (nf) as well as in the spi-
ral ganglion cells (sg), whose structures are
clearly stained by the antibody directed
against neurofilament heavy chain NFH.
The merged picture shows partial overlap
of ESRRB and NFH in the nerve fibers and
the spiral ganglion cells.
(G–I) Magnified image of ESRRB and NFH
staining in the region of the organ of Corti. NFH is expressed at the base of outer (OHCs) and inner (IHC) hair cells, whereas ESRRB is clearly
not expressed in those cells, but in supporting cells (3).
(J–L) Magnified image of ESRRB and NFH staining in the neurites that connect the hair cells to the spiral ganglia. ESRRB is expressed in
the nerve fibers as well as in cells surrounding the nerve fibers, whereas NFH is only expressed in the neurons. The merged picture shows
colocalization of ESRRB and NFH in the nerve fibers.
(M–O)Magnified image of ESRRB andNFH staining in a spiral ganglion. Both ESRRB andNFH are expressed in the spiral ganglion neurons and
fibers, although their localization does not completely overlap.express ESRRB (supporting cells andmesothelial cells) are de-
rived fromnonsensoryepithelium,andsuchaﬁnding iscon-
sistent with the expression pattern observed during embry-
onic development. Both the RNA in situ hybridization and
the immunohistochemistry show no expression of ESRRB
in the developing cochlear hair cells. Themorenarrow local-
ization of ESRRB in immunohistochemistry as presented by
Chen andNathansmight be due to variations in experimen-
tal conditions and to the use of different antibodies.
In the affected individuals of family TR-21, TEOAEs were
absent; this ﬁnding is indicative of compromised outer
hair cell function. Because ESRRB is not expressed in these
cells, the loss of outer hair cell function is probably a sec-
ondary effect. Although ESRRB is abundantly expressed
in both the cochlea and the vestibulum during embryonic
development in mice, the hearing-impaired individuals of
the various families do not show symptoms of vestibular
dysfunction. This suggests redundancy for ESRRB in the
vestibulum but not in the cochlea.The AFrom a single gene in the ancestor of bilaterian meta-
zoans, twowaves of duplication led to the three ESRR genes
present in vertebrates, ESRRA, ESRRB, and ESRRG.37 All
three paralogues play an important role, both during devel-
opment and in adulthood. In vertebrates, we have themost
knowledge of the function of ESRRA,whichhas been impli-
cated in estrogen signaling andmammary-tumorbiology,38
and the expression levels of both ESRRA and ESRRG are used
as prognostic indicators in breast and ovarian cancer.39–41
Furthermore, ESRRA has been implicated in mitochondrial
biogenesis and lipidmetabolism.42,43 In zebraﬁsh, the esrra
receptor has been shown to control morphogenetic move-
ments during gastrulation.44
Little is known about the role of ESRRB in humans. In
mice, Esrrb is essential for normal placentation and ex-
hibits a highly speciﬁc expression pattern in extra-embry-
onic tissue from 5.5 until 8.5 days postcoitum (dpc).45
From 11.5 until 16 dpc, Esrrb is expressed in primordial
germ cells.46 Esrrb/ mice die at approximately 10.5 dpcmerican Journal of Human Genetics 82, 125–138, January 2008 135
but can be rescued by aggregation with tetraploid wild-
type cells.45,46 Rescued Esrrb null mice were fertile but, in-
terestingly, exhibited problems with walking and showed
circling and head-tossing behavior.46 The latter are indica-
tive of an inner-ear dysfunction. Whereas the murine Esrrb
is essential for placentation, apparently the human ortho-
log might only be required for proper hearing. Recently,
Chen and Nathans conﬁrmed the inner-ear phenotype of
rescued Esrrb/ mice by generating conditional Esrrb/
mice.36 These studies revealed that ESRRB is essential for
the development of the marginal cells and thereby for
the development and function of the stria vascularis as
a whole. Disturbed endolymph production in these mice
results in an aberrant inner-ear ﬂuid homeostasis and as
a consequence in defective hearing and balance.
Although defects in ESRRB clearly affect cellular pro-
cesses within the inner ear, the exact molecular mecha-
nism by which ESRRB acts upon putative target genes re-
mains elusive. ESRRs, including ESRRB, are implicated in
mediating the effects of estrogens, thyroid hormone, and
glucocorticoid hormone that are all important for inner-
ear development and function. Thyroid hormone and its
receptors TRHA and TRHB are essential for several aspects
of cochlear development and maturation.47–50 Studies in
Thra and Thrb knockout mice indicate that both receptors
are involved in the development of the endocochlear
potential, in which the stria vascularis is known to have
a major role.51 Because ESRRB is suggested to inﬂuence
the thyroid hormone pathway,52,53 the concomitant
high expression of Esrrb in the developing stria vascularis
suggests that ESRRB might mediate the effect of both thy-
roid receptors a and b in this region.
ESRRB and other ESRRs bind to both estrogen-responsive
elements and steroid-responsive elements, and estrogen
has a role in preservation of hearing during aging in hu-
man adults. Such a role is consistent with the decline in
hearing observed in the estrogen receptor b knockout
mouse.54 The early onset, severe-to-profound hearing loss
in the DFNB35 families, however, seems not to be in agree-
ment with the proposed role for estrogen in the mainte-
nance of hearing.
Alterations in transcription mediated by the glucocorti-
coid receptor might also contribute to the phenotype of
the present ESRRB mutations because the glucocorticoid
receptor is, like ESRRB, widely expressed during and after
maturation of the mouse and rat cochlea. In addition,
ESRRB might repress transcriptional activity mediated by
the glucocorticoid receptor.55
In conclusion, this study describes the identiﬁcation of
ESRRB as the gene involved in autosomal recessive hearing
impairment DFNB35. The fact that the frame-shift muta-
tion and the missense mutations result in a comparable
clinical phenotype suggests that the molecular mechanism
underlying the hearing impairment is similar and proba-
bly results from a loss of function. This is corroborated by
the phenotype of the conditional Esrrb/ mice. In these
mice, defective hearing and balance coincide with dis-136 The American Journal of Human Genetics 82, 125–138, Januaryturbed endolymph production and ion homeostasis, and
it is likely that human ESRRB is crucial for these processes
as well. Further characterization of the exact molecular
mechanisms by which genetic defects in ESRRB cause non-
syndromic hearing loss will contribute to the understand-
ing of the processes that are essential for normal hearing
and might therefore be of great importance for therapeutic
intervention.
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